Welcome to Business Insider‘s daily healthcare newsletter, your daily dose of pharma, biotech, and healthcare news. Subscribe here to get this newsletter in your inbox every weekday.
Hello,
Today in healthcare news: The pitch deck that convinced J&J to bet on a new kind of healthcare company, Pfizer plans to submit its vaccine in November for emergency authorization if it works, and an inside look at how Gilead developed remdesivir, a drug that now faces questions about how effective it is in treating COVID-19.
Courtesy Keeps
See the pitch deck 2 former Googlers used to raise $47 million and convince Johnson & Johnson to bet on the hottest part of healthcare
- Thirty Madison in August raised $47 million from investors including Johnson & Johnson Innovation.
- The two-year-old startup treats conditions like migraines with three distinct companies: Cove, Evens, and Keeps.
- Thirty Madison’s business has shot up because of the pandemic, but also deep-seeded issues in the US healthcare system.
Read the full story from Blake Dodge here>>
Pfizer plans to submit its COVID-19 vaccine for FDA authorization in late November — if human trials show it works
- Pfizer and its German partner BioNTech could apply for emergency-use authorization for their COVID-19 vaccine in late November, Pfizer said Friday.
- The companies would submit their application to the Food and Drug Administration in the third week of November if late-stage human trials go well, Pfizer said.
- This is the most concrete time frame a leading vaccine developer in the West has given for an emergency-use-authorization application.
- Pfizer's announcement indicates there is no chance its vaccine will be authorized for use before the US election on November 3.
Read the full story from Grace Dean here>>
Lab technicians operate a machine to wash empty vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility in La Verne, California, U.S. March 18, 2020.
Gilead Sciences Inc/Handout via Reuters
Gilead Sciences Inc/Handout via Reuters
Here's how the biotech giant Gilead created the leading coronavirus drug remdesivir, which now faces questions over its effectiveness at treating COVID-19
- Remdesivir is an experimental drug that became the leading coronavirus treatment option, after previously failing as an Ebola therapy.
- President Donald Trump received the antiviral as part of his COVID-19 care, as have thousands of hospitalized coronavirus patients.
- But the drug faces questions about whether or not it actually helps patients. A massive trial run by the World Health Organization found it didn't reduce mortality, ventilator use, or shorten hospitalizations.
More stories we're reading:
- Pfizer and Moderna are neck-and-neck in the race to deliver the first effective coronavirus vaccine. Here's everything we know about the timeline and when you might be able to get a shot. (Business Insider)
- Insider the fall of the CDC (Come for all the concerning details, stay for the drama around trying to get a dog into the US) (ProPublica)
- Meet the 11 companies racing to make a COVID-19 test that's as quick and easy to take as a pregnancy test (Business Insider)
- Meet the people in charge of deciding when key vaccine trials are done (ProPublica)
Subscribe to this newsletter here.
- Lydia
Read the original article on Business Insider